Skip to main content

Advertisement

Log in

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

  • Letter
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  CAS  PubMed  Google Scholar 

  2. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394

    Article  CAS  PubMed  Google Scholar 

  3. Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K (2013) Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8:250–253

    Article  CAS  PubMed  Google Scholar 

  4. van Geffen WH, Hiltermann TJ, Groen HJ (2013) Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. J Thorac Oncol 8:e1–e2

    Article  PubMed  Google Scholar 

  5. Toffart AC, Minet C, Raynard B, Schwebel C, Hamidfar-Roy R, Diab S, Quetant S, Moro-Sibilot D, Azoulay E, Timsit JF (2011) Use of intensive care in patients with nonresectable lung cancer. Chest 139:101–108

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

ACT: Roche, Boehringer Ingelheim; XD: Boehringer Ingelheim; CAV: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; BM: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; PF: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; DMS: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; NG, CC, MD, AP and JFT declared that they have no competing interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anne-Claire Toffart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toffart, AC., Dhalluin, X., Girard, N. et al. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Med 41, 164–165 (2015). https://doi.org/10.1007/s00134-014-3535-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-014-3535-x

Keywords

Navigation